Tumor mutational burden is not predictive of cytotoxic chemotherapy response
Background High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TM...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1781997 |
id |
doaj-eb75b2f432e0443d8eded34b45434e64 |
---|---|
record_format |
Article |
spelling |
doaj-eb75b2f432e0443d8eded34b45434e642021-09-24T14:41:25ZengTaylor & Francis GroupOncoImmunology2162-402X2020-01-019110.1080/2162402X.2020.17819971781997Tumor mutational burden is not predictive of cytotoxic chemotherapy responseMina Nikanjam0Paul Riviere1Aaron Goodman2Donald A. Barkauskas3Garrett Frampton4Razelle Kurzrock5UC San Diego Moores Cancer CenterUC San Diego Moores Cancer CenterUC San Diego Moores Cancer CenterKeck School of Medicine, University of Southern CaliforniaFoundation MedicineUC San Diego Moores Cancer CenterBackground High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TMB and outcome in patients with solid tumors receiving cytotoxic chemotherapy. Methods University of California San Diego patients who received cytotoxic chemotherapy within one year after biopsy for TMB evaluation were included in a retrospective analysis. Physician notes and imaging reports in the electronic medical record were reviewed to determine clinical benefit and progression-free survival (PFS). Results Among 1526 patients with TMB availability, there were 294 eligible patients who received chemotherapy. There were no significant differences in TMB between those with stable disease ≥6 months/partial response/complete response versus others (t-test, p = .22). There were no significant differences in PFS for patients with TMB <10 vs. TMB ≥10 mutations/Mb (log-rank test, median and 95% CI: 6.0 (4.8–7.4) vs. 5.4 (4.3–6.6) months; p = .21). Nor were there significant differences in PFS for patients with a TMB <10 vs. TMB ≥10 mutations/mb for breast (p = .07), lung (p = .47), or gastrointestinal cancer (p = .53). Conclusions In summary, TMB was not predictive of stable disease ≥6 months/partial response/complete response or PFS in patients receiving cytotoxic chemotherapy. Trials Registration NCT02478931http://dx.doi.org/10.1080/2162402X.2020.1781997tumor mutational burdencytotoxic chemotherapyoncologybiomarker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mina Nikanjam Paul Riviere Aaron Goodman Donald A. Barkauskas Garrett Frampton Razelle Kurzrock |
spellingShingle |
Mina Nikanjam Paul Riviere Aaron Goodman Donald A. Barkauskas Garrett Frampton Razelle Kurzrock Tumor mutational burden is not predictive of cytotoxic chemotherapy response OncoImmunology tumor mutational burden cytotoxic chemotherapy oncology biomarker |
author_facet |
Mina Nikanjam Paul Riviere Aaron Goodman Donald A. Barkauskas Garrett Frampton Razelle Kurzrock |
author_sort |
Mina Nikanjam |
title |
Tumor mutational burden is not predictive of cytotoxic chemotherapy response |
title_short |
Tumor mutational burden is not predictive of cytotoxic chemotherapy response |
title_full |
Tumor mutational burden is not predictive of cytotoxic chemotherapy response |
title_fullStr |
Tumor mutational burden is not predictive of cytotoxic chemotherapy response |
title_full_unstemmed |
Tumor mutational burden is not predictive of cytotoxic chemotherapy response |
title_sort |
tumor mutational burden is not predictive of cytotoxic chemotherapy response |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2020-01-01 |
description |
Background High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TMB and outcome in patients with solid tumors receiving cytotoxic chemotherapy. Methods University of California San Diego patients who received cytotoxic chemotherapy within one year after biopsy for TMB evaluation were included in a retrospective analysis. Physician notes and imaging reports in the electronic medical record were reviewed to determine clinical benefit and progression-free survival (PFS). Results Among 1526 patients with TMB availability, there were 294 eligible patients who received chemotherapy. There were no significant differences in TMB between those with stable disease ≥6 months/partial response/complete response versus others (t-test, p = .22). There were no significant differences in PFS for patients with TMB <10 vs. TMB ≥10 mutations/Mb (log-rank test, median and 95% CI: 6.0 (4.8–7.4) vs. 5.4 (4.3–6.6) months; p = .21). Nor were there significant differences in PFS for patients with a TMB <10 vs. TMB ≥10 mutations/mb for breast (p = .07), lung (p = .47), or gastrointestinal cancer (p = .53). Conclusions In summary, TMB was not predictive of stable disease ≥6 months/partial response/complete response or PFS in patients receiving cytotoxic chemotherapy. Trials Registration NCT02478931 |
topic |
tumor mutational burden cytotoxic chemotherapy oncology biomarker |
url |
http://dx.doi.org/10.1080/2162402X.2020.1781997 |
work_keys_str_mv |
AT minanikanjam tumormutationalburdenisnotpredictiveofcytotoxicchemotherapyresponse AT paulriviere tumormutationalburdenisnotpredictiveofcytotoxicchemotherapyresponse AT aarongoodman tumormutationalburdenisnotpredictiveofcytotoxicchemotherapyresponse AT donaldabarkauskas tumormutationalburdenisnotpredictiveofcytotoxicchemotherapyresponse AT garrettframpton tumormutationalburdenisnotpredictiveofcytotoxicchemotherapyresponse AT razellekurzrock tumormutationalburdenisnotpredictiveofcytotoxicchemotherapyresponse |
_version_ |
1717369705936715776 |